株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:セリアック病

Market Spotlight: Celiac Disease

発行 Datamonitor Healthcare 商品コード 633145
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
注目市場の分析:セリアック病 Market Spotlight: Celiac Disease
出版日: 2019年11月18日 ページ情報: 英文 30 Pages
概要

世界のセリアック病の有病者数は2016年の約8850万人、2025年には9740万人に増加すると予測されています。

当レポートでは、世界のセリアック病の治療薬の市場を調査し、疾患の背景・概要、有病者数の10ヵ年予測、主な治療法、主なパイプライン薬の概要、ライセンシング・資産買収など企業間の主な取引の動向、特許情報、臨床試験の状況などをまとめています。

概要

主な要点

疾患の背景

  • サブタイプ

治療

疫学

パイプライン薬

今後の主なイベント

ライセンシング・資産買収契約

  • 武田薬品工業による資金供給・買収準備の可能性も

親特許

臨床試験環境

文献

付録

目次
Product Code: DMKC0181038

This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 89.9 million prevalent cases of celiac disease worldwide, and forecasts that number to increase to 98.8 million prevalent cases by

2026. Prevalence of celiac disease is highest in Europe and Northern America, and lowest in Africa and Oceania. The majority of industry-sponsored drugs in active clinical development for celiac disease are in Phase II, with only one drug in Phase III.

Therapies in development for celiac disease focus on targets such as zonulin and zonulin receptor, interleukin-15, interleukin-15 receptor, and gluten. Pipeline drugs for celiac disease are administered via the oral and intravenous routes.

The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 13.6%, and the average probability a drug advances from Phase III is 68.3%. Drugs, on average, take 9.0 years from Phase I to approval in the overall autoimmune/immunology space.

There have been seven licensing and asset acquisition deals involving celiac disease drugs during 2014-19. The largest deal during the period was the $800m collaboration and license agreement signed in May 2019 between Parvus and Genentech to develop, manufacture, and commercialize novel Navacim therapeutics for the treatment of inflammatory bowel disease, autoimmune liver diseases, and celiac disease.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for celiac disease have been in the mid and late phases of development, with 91% of trials in Phase II-III, and only 9% in Phase I.

The US has the highest number of celiac disease clinical trials globally. Clinical trial activity in the celiac disease space is dominated by completed trials. Innovate Biopharmaceuticals has the highest number of completed clinical trials for celiac disease, with six trials.

Innovate Biopharmaceuticals leads industry sponsors with the highest overall number of clinical trials for celiac disease.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

7 Subtypes

9 TREATMENT

10 EPIDEMIOLOGY

14 PIPELINE DRUGS

18 RECENT EVENTS AND ANALYST OPINION

18 TAK-101 for Celiac Disease (October 21, 2019)

20 KEY UPCOMING EVENTS

21 PROBABILITY OF SUCCESS

22 LICENSING AND ASSET ACQUISITION DEALS

22 Takeda Adds Celiac Disease Candidate To GI Efforts

22 Anokion Acquires Its Own Spinout, Kanyos

23 GSK Buys One Of Eight Firms Formed In VC Partnership With Avalon

23 Parvus, Genentech Collaborate On IBD, Celiac And Liver Disease

24 CLINICAL TRIAL LANDSCAPE

25 Sponsors by status

26 Sponsors by phase

26 Phase II Study Shows Antigen-Specific Immune Tolerance Is Possible In Autoimmune Diseases

28 BIBLIOGRAPHY

29 APPENDIX

LIST OF FIGURES

  • 12 Figure 1: Trends in prevalent cases of celiac disease, 2017-26
  • 14 Figure 2: Overview of pipeline drugs for celiac disease in the US
  • 14 Figure 3: Pipeline drugs for celiac disease, by company
  • 15 Figure 4: Pipeline drugs for celiac disease, by drug type
  • 15 Figure 5: Pipeline drugs for celiac disease, by classification
  • 19 Figure 6: TAK-101 for Celiac Disease (October 21, 2019): Phase IIa - Safety & Efficacy
  • 20 Figure 7: Key upcoming events in celiac disease
  • 21 Figure 8: Probability of success in the celiac disease pipeline
  • 22 Figure 9: Licensing and asset acquisition deals in celiac disease, 2014-19
  • 24 Figure 10: Clinical trials in celiac disease
  • 24 Figure 11: Top 10 drugs for clinical trials in celiac disease
  • 25 Figure 12: Top 10 companies for clinical trials in celiac disease
  • 25 Figure 13: Trial locations in celiac disease
  • 26 Figure 14: Celiac disease trials status
  • 26 Figure 15: Celiac disease trials sponsors, by phase

LIST OF TABLES

  • 11 Table 1: Prevalent cases of celiac disease, 2017-26
  • 13 Table 2: Prevalence proportions of celiac disease, by age group, 2017
  • 16 Table 3: Pipeline drugs for celiac disease in the US
  • 18 Table 4: TAK-101 for Celiac Disease (October 21, 2019)